New data
presented
@TCT2022

We all know about the condition of heart failure. We just haven’t been able to treat it the right way—until now.

We’ve had to watch the devastating symptoms of heart failure as the disease progresses and the damage becomes irreversible.

It’s time to reshape the treatment course for patients.

Cardiac Dimensions is on a mission to bring more success to the treatment of heart failure patients.

Introducing the Carillon Mitral Contour System®

A completely different and much earlier approach to treating functional mitral regurgitation (FMR) than any other device therapy currently available to patients.

The goal: Treat the condition—not just the symptoms.

The Carillon System is designed to work with the natural structure and function of the heart to help treat the condition of FMR as well as the related symptoms.

We believe the Carillon Therapy is a smarter solution to help patients feel better and live longer lives.

Discover the Carillon System

U.S. EMPOWER Clinical Trial

NOW ENROLLING

For heart failure patients with large ventricles + functional mitral regurgitation

LEARN MORE

Our focus is to bring a better treatment option to the millions of people who suffer from heart failure with FMR.

One that’s less invasive.

One that saves time.

One that doesn’t prevent other treatments if needed.

One that patients worldwide welcome.

The Carillon Therapy is a good option for our patients. According to published research, there’s a demonstrated positive relationship between the Carillon Therapy and improving the quality-of-life metrics our patients care about.

LEARN MORE

Why the Carillon Mitral Contour System Matters

“Our patients don’t care if they have regurgitant volume when they come to the hospital. Their focus is around symptoms, quality-of-life, hospitalizations and, as the ultimate goal, long-term survival.”

Stefan Anker, MD

Professor of Cardiology

Charité University
Berlin, Germany

“I am very excited to launch the EMPOWER Trial. This will be the first time where we are able to study early intervention with a device in heart failure. This is an extremely large patient population that is currently not being studied by other novel therapies.”

Samir Kapadia, MD

Chairman of the Department of Cardiovascular Medicine

Cleveland Clinic
Cleveland, OH

“The improved survival rate outcomes for patients receiving the Carillon device compared to medical management of these heart failure patients is simply impressive.”

Janusz Lipiecki, MD

Center for Interventional Cardiology of Pôle Santé République

Clermont-Ferrand
Auvergne, France

“I’m so pleased. I’m not dizzy anymore. I don’t have breathing problems anymore. I don’t have to take pauses when shopping. I can do everything by myself again. Hooray!”

Gandula

Carillon patient

Germany

Latest News

January 26, 2023

Cardiac Dimensions Appoints Angie Swenson as Vice President, Clinical Operations

January 5, 2023

Cardiac Dimensions Raises $35 Million In Series D Financing

September 22, 2021

Cardiac Dimensions Included in the New 2021 ESC Guidelines for Heart Failure Management

Join our mailing list for invitations to studies along with company announcements.

NOTE: The Carillon Mitral Contour System has received CE Mark (0344) and is available for sale in Europe and other countries that recognize CE Mark.

CAUTION: Investigational Device. Limited by United States law to investigational use.

NOTE: The Carillon Mitral Contour System has received CE Mark (0344) and is available for sale in Europe and other countries that recognize CE Mark.

CAUTION: Investigational Device. Limited by United States law to investigational use.